HTG Molecular Diagnostics Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 107

Employees

  • Stock Symbol
  • HTGMQ

Stock Symbol

HTG Molecular Diagnostics General Information

Description

HTG Molecular Diagnostics Inc is a life science company whose mission is to advance precision medicine through its transcriptome-wide profiling and medicinal chemistry technologies. The company derives revenue from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based HTG EdgeSeq research use only assays and from sample processing services performed in its VERI/O laboratory. The company operates in one segment and its customers and distributors are located in the United States and Europe.

Contact Information

Formerly Known As
High Throughput Genomics, High Throughput Genomics Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3430 East Global Loop
  • Tucson, AZ 85706
  • United States
+1 (877)
Primary Industry
Discovery Tools (Healthcare)
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 3430 East Global Loop
  • Tucson, AZ 85706
  • United States
+1 (877)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HTG Molecular Diagnostics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
2.82K

HTG Molecular Diagnostics Financials Summary

As of 31-Mar-2023, HTG Molecular Diagnostics has a trailing 12-month revenue of $6.21M.

In Thousands,
USD
TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV (1,399) 3,604 27,548 4,754
Revenue 6,214 6,366 8,907 8,549
EBITDA (19,092) (20,234) (15,367) (18,739)
Net Income (20,152) (21,594) (17,145) (20,870)
Total Assets 10,866 17,778 30,461 35,198
Total Debt 3,981 4,834 11,710 12,644
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HTG Molecular Diagnostics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore HTG Molecular Diagnostics‘s full profile, request access.

Request a free trial

HTG Molecular Diagnostics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore HTG Molecular Diagnostics‘s full profile, request access.

Request a free trial

HTG Molecular Diagnostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
HTG Molecular Diagnostics Inc is a life science company whose mission is to advance precision medicine through its trans
Discovery Tools (Healthcare)
Tucson, AZ
107 As of 2025

Milford, MA
 

Saclay, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HTG Molecular Diagnostics Competitors (16)

One of HTG Molecular Diagnostics’s 16 competitors is SeraCare, a Formerly PE-Backed company based in Milford, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SeraCare Formerly PE-Backed Milford, MA
CIS Bio International Formerly PE-Backed Saclay, France
ABM (Canada) Corporation Richmond, Canada
Oxford Gene Technology Formerly VC-backed Kidlington, United Kingdom
Bio-Techne Corporation Minneapolis, MN
You’re viewing 5 of 16 competitors. Get the full list »

HTG Molecular Diagnostics Patents

HTG Molecular Diagnostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024145483-A1 Compounds for use in the treatment of cancer and methods of making and using the same Inactive 28-Dec-2022
US-20240425914-A1 Epitranscriptome evaluation Pending 01-Sep-2021
WO-2023034747-A1 Epitranscriptome evaluation Inactive 01-Sep-2021
WO-2023034747-A9 Epitranscriptome evaluation Inactive 01-Sep-2021
AU-2019418340-A1 Methods of detecting dna and rna in the same sample Inactive 31-Dec-2018 C12Q1/6874
To view HTG Molecular Diagnostics’s complete patent history, request access »

HTG Molecular Diagnostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HTG Molecular Diagnostics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore HTG Molecular Diagnostics‘s full profile, request access.

Request a free trial

HTG Molecular Diagnostics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view HTG Molecular Diagnostics’s complete esg history, request access »

HTG Molecular Diagnostics FAQs

  • When was HTG Molecular Diagnostics founded?

    HTG Molecular Diagnostics was founded in 1997.

  • Where is HTG Molecular Diagnostics headquartered?

    HTG Molecular Diagnostics is headquartered in Tucson, AZ.

  • What is the size of HTG Molecular Diagnostics?

    HTG Molecular Diagnostics has 107 total employees.

  • What industry is HTG Molecular Diagnostics in?

    HTG Molecular Diagnostics’s primary industry is Discovery Tools (Healthcare).

  • Is HTG Molecular Diagnostics a private or public company?

    HTG Molecular Diagnostics is a Public company.

  • What is HTG Molecular Diagnostics’s stock symbol?

    The ticker symbol for HTG Molecular Diagnostics is HTGMQ.

  • What is HTG Molecular Diagnostics’s current revenue?

    The trailing twelve month revenue for HTG Molecular Diagnostics is $6.21M.

  • Who are HTG Molecular Diagnostics’s competitors?

    SeraCare, CIS Bio International, ABM (Canada), Oxford Gene Technology, and Bio-Techne are some of the 16 competitors of HTG Molecular Diagnostics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process